Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22107761 | 0.87 | POLG (0.51) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL24235900 | 0.87 | POLG (0.51) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL22107760 | 0.85 | ADORA3 (0.44) | POLBPNPHPRT1NT5EADORA3 | |
| SCHEMBL22107759 | 0.85 | POLG (0.49) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL22107765 | 0.84 | P2RY1 (0.57) | POLBP2RY2P2RY1 | |
| SCHEMBL22107720 | 0.83 | ADORA3 (0.52) | POLBPNPHPRT1ADORA3 | |
| SCHEMBL21050291 | 0.81 | POLG (0.50) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL21050283 | 0.81 | POLG (0.50) | POLGPOLBPNPFUT5P2RY2 | |
| SCHEMBL24235873 | 0.80 | P2RY1 (0.38) | P2RY2P2RY4P2RY6P2RY1ADORA3 | |
| SCHEMBL22107750 | 0.79 | POLG (0.51) | POLGPOLBPNPFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | PNP, TYMP, HAVCR2 | POLG 168/4885POLB 40/4885PNP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.